SCHEMBL20764282

SCHEMBL20764282

CC(C)Oc1ccc(-c2ccc(C(=O)Nc3ccc(Cl)cc3)s2)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESRRG P62508 6/20 0.70
ESR1 P03372 2/20 0.70
KDM4E B2RXH2 3/20 0.68
SMN1; SMN2 Q16637 2/20 0.68
LMNA P02545 1/20 0.68
MAPKAPK2 P49137 1/20 0.57
MAPT P10636 2/20 0.57
RXFP1 Q9HBX9 1/20 0.54
CNR1 P21554 2/20 0.54
NPC1 O15118 3/20 0.53
RAB9A P51151 3/20 0.53
PPARG P37231 2/20 0.53
NCOA2 Q15596 1/20 0.53
NCOA1 Q15788 1/20 0.53
NCOA3 Q9Y6Q9 1/20 0.53
PTPN11 Q06124 2/20 0.53
PTPN2 P17706 1/20 0.53
NR2E3 Q9Y5X4 1/20 0.53
NCOR2 Q9Y618 1/20 0.53
ESR2 Q92731 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20764259 0.89 ESRRG (0.72) ESRRGESR1KDM4ESMN1; SMN2LMNA
SCHEMBL20764121 0.85 KDM4E (0.64) ESRRGESR1KDM4ESMN1; SMN2LMNA
SCHEMBL20764041 0.83 ESRRG (0.67) ESRRGESR1KDM4ESMN1; SMN2LMNA
SCHEMBL20764016 0.83 ESRRG (1.00) ESRRGESR1KDM4ESMN1; SMN2LMNA
SCHEMBL20764080 0.82 ESRRG (0.78) ESRRGESR1KDM4ESMN1; SMN2LMNA
SCHEMBL5983429 0.81 PPARG (0.65) ESRRGESR1MAPTPPARG
SCHEMBL3973585 0.81 PPARG (0.65) ESRRGESR1MAPTPPARG
SCHEMBL20764112 0.81 ESRRG (0.67) ESRRGESR1KDM4ESMN1; SMN2LMNA
SCHEMBL20764058 0.80 KDM4E (0.68) ESRRGESR1KDM4ESMN1; SMN2LMNA
SCHEMBL20764071 0.80 ESRRG (0.71) ESRRGESR1KDM4ESMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11795162-B2 Modulators of the estrogen-related receptor SAINT LOUIS UNIVERSITY (US) 2023-10-24 US disclosed
US-11795162-B2 Modulators of the estrogen-related receptor SAINT LOUIS UNIVERSITY (US) 2023-10-24 US disclosed
US-20200247792-A1 ERR INVERSE AGONISTS SAINT LOUIS UNIVERSITY (US) 2020-08-06 US disclosed
WO-2019036562-A1 ERR INVERSE AGONISTS SAINT LOUIS UNIVERSITY (US) 2019-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200247792-A1 ERR INVERSE AGONISTS ESRRA, ESRRB, ESR2 ESRRG 4/4885ESR1 6/4885KDM4E 1194/4885
US-11795162-B2 Modulators of the estrogen-related receptor ESR2, GPER1, ESRRG ESRRG 3/4885ESR1 4/4885KDM4E 1278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.